ARCHIVES

Clinical Research; Duke Received Several Warnings from OPRR, Letters Indicate

This article is from The Cancer Letter archive.

Vol. 25 No. 19 | May 14, 1999

Download PDF Visit The Full Archive

Related Articles

Chemical, Viral Carcinogenesis Should Not Be Separated: Shimkin

July 14, 1978

First-Line Bendamustine Doubles PFS In Non-Hodgkin and Mantle Cell Lymphoma

February 22, 2013

In Brief: ACS to support $2 Billion NCI Budget; NCAB Backs Minority Enhancement Core Supplements

February 19, 1988

ASCO Annual Meeting: PARP Inhibitors Show Promise Against Breast Cancer In Small Phase II Studies

June 5, 2009

NCAB working Group Is Not Subject To Open Meetings Law, NCI Official Says

December 9, 1994

ODAC Recommends Femara Campath For FDA Approval.

January 5, 2001